(Q35174508)

6 August 2017

1 reference

title

Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? (English)

1 reference

6 August 2017

1 reference

1 reference

Katherine H Fiala

1

1 reference

6 August 2017

Jacqueline Whetteckey

series ordinal

2

1 reference

6 August 2017

Bala V Manyam

series ordinal

3

1 reference

6 August 2017

publication date

1 August 2003

1 reference

6 August 2017

number of pages

7

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

321-327

1 reference

L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II)

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

1 reference

7 January 2021

Parkinson's disease, melanoma, and levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Uveal malignant melanoma and levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Choroidal melanoma and levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Levodopa and melanoma: three cases and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Development of malignant melanoma after levodopa therapy for Parkinson's disease. Report of a case and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Impaired levodopa response in Parkinson's disease during melanoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Lid melanoma and parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Levodopa, melanoma, and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Safety of long-term levodopa therapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

[Levodopa and malignant melanoma--case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma]

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Gene responsible for most malignant melanomas is discovered

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Levodopa therapy and the risk of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Risk of second primary malignancies in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Melanoma and levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

The use of L-dopa and carbidopa in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900040-3

7 January 2021

10.1016/S1353-8020(03)00040-3

Identifiers

DOI

1 reference

6 August 2017

1 reference